Take a bite out of our new issue, where we examine Africa’s forgotten crops and the secrets of fresh food.

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

The therapy, called reni-cel, is designed to treat sickle cell disease and beta thalassemia — the same two diseases targeted by Casgevy, a similar gene editing treatment from Vertex Pharmaceuticals ...

In a world-first development for biosecurity management, the NSW Department of Primary Industries and Regional Development ...

New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a ...

Why does the rooster crow and the hen does not? This question prompted the scientist Arnold Adolph Berthold to castrate a ...